In conclusion, EVA1A improves hepatic I/R injury through inhibiting NLRP3 activation by inducing autophagy in KCs, suggesting that EVA1A may be a drug target for clinical treatment of hepatic I/R injury [63]. This evidence concerns the gene NLRP3 and dry eye syndrome.